To the ‘Imaxio’: Vaccine Technology Seeks Immune Boost
By Marie Powers
Wednesday, September 11, 2013
After a decade of work, French vaccine developer Imaxio SA achieved a significant milestone when IMX313, its pro-immunogenic technology, was administered for the first time in humans in a Phase I tuberculosis (TB) vaccine trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.